Harvard Medical School (HMS and HSDM)
Trial Pipeline
Star Matrix vs Autogenous Graft for Gingival Augmentation: Split-Mouth RCT
NCT07440303
Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease
NCT06602544
The Effect of Work Requirements in SNAP in Virginia
NCT04888832
Vertical Soft Tissue Augmentation With CTG vs ADM
NCT05729607
Efficacy of a Dental Implant System for Immediate Restoration
NCT06651502
Buccal Graft + Collagen Matrix Versus Free Gingival Graft for Keratinized Mucosa Augmentation at Implant Sites
NCT05844475
Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences
NCT05576922
Effect of Cash Benefits on Health Care Spending
NCT07381049
Cash Benefits and Reproductive/Perinatal Health
NCT05782660
The Effect of Community Building Through Virtual, Team-Based Exercise on Burnout
NCT05194410
Effect of Using Placental Membranes on Healing and Post-op Pain After Gum Surgery
NCT04957342
Rt-fMRI Neurofeedback and AH in Schizophrenia
NCT03504579
Community Partnership to Examine Racial and Ethnic Differences in Health Care for Hypertension and Diabetes
NCT00379652
Computerized and Mailed Reminders in Increasing the Rate of Colorectal Cancer Screening in Adults With an Average Risk for Colorectal Cancer
NCT00355004
Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169065
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for Harvard Medical School (HMS and HSDM) Shows
According to the ClinicalTrials.gov registry, Harvard Medical School (HMS and HSDM) is linked to 71 US clinical trials across every stage of research activity. Of those, 60 studies are currently recruiting — about 85% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 8% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Harvard Medical School (HMS and HSDM) reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Harvard Medical School (HMS and HSDM) is Implant Complication with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.